Cutaneous lymphoma incidence patterns in the United States: A population-based study of 3884 cases

Blood

Volumn 113, Issue 21, 2009, Pages 5064-5073

  Bradford, Porcia T ^a   Devesa, Susan S ^a   Anderson, William F ^a   Toro, Jorge R ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; ASIAN AMERICAN; B CELL LYMPHOMA; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER REGISTRY; CANCER SURVIVAL; CUTANEOUS T CELL LYMPHOMA; EUROPEAN AMERICAN; FEMALE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOSIS FUNGOIDES; PACIFIC ISLANDER; POPULATION RESEARCH; PRIORITY JOURNAL; RACE DIFFERENCE; SEX RATIO; SEZARY SYNDROME; SKIN LYMPHOMA; SURVIVAL RATE; TREND STUDY; UNITED STATES; ADOLESCENT; AGE DISTRIBUTION; CHILD; ETHNIC GROUP; INCIDENCE; MIDDLE AGED; RACE; SEX DIFFERENCE; SKIN TUMOR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CHILD; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; FEMALE; HUMANS; INCIDENCE; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; SEX FACTORS; SKIN NEOPLASMS; SURVIVAL RATE; UNITED STATES; YOUNG ADULT;

EID: 67149145235     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-10-184168     Document Type: Article

References (55)

1. Leboit PE, Burg G, Weedon D, Sarasin A. Pathology and Genetics: Skin Tumors. Lyon, France: IARC Press; 2006.
2. Riou-Gotta MO, Fournier E, Mermet I, et al. Primary cutaneous lymphomas: a population-based descriptive study of 71 consecutive cases diagnosed between 1980 and 2003. Leuk Lymphoma. 2008;49:1537-1544.
3. Rizvi MA, Evens AM, Tallman MS, Nelson BP, Rosen ST. T-cell non Hodgkin lymphoma. Blood. 2006;107:1255-1264.
4. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol. 2007;143:854-859.
5. Pimpinelli N, Masala G, Santucci M, et al. Primary cutaneous lymphomas in Florence: a population-based study 1986-2005 [abstract]. Ann Oncol. 1996;7(suppl 3):130.
6. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768-3785.
7. Assaf C, Gellrich S, Steinhoff M, et al. Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology. J Dtsch Dermatol Ges. 2007;5:662-668. (Pubitemid 47099799)
8. Dummer R, Asogoe K, Cozzio A. Recent advances in cutaneous lymphomas. J Dermatol Science. 2007;48:157-167.
9. Trento E, Castilleti C, Ferraro C, et al. Human herpesvirus 8 infection in patients with cutaneous lymphoproliferative diseases. Arch Dermatol. 2005;141:1235-1242. (Pubitemid 41498920)
10. Gupta RK, Ramble J, Tong CY, et al. Cytomegalovirus seroprevalence is not higher in patients with mycosis fungoides/Sezary syndrome. Blood. 2006;107:1241-1242. (Pubitemid 43156336)
11. Tothova SM, Bonin S, Trevisan G, Stanta G. Mycosis fungoides: is it a Borrelia burgdorefi-associated disease? Br J Cancer. 2006;94:879-883.
12. Morales-Suárez-Varel MM, Olsen J, Johansen P, et al. Occupational exposures and mycosis fungoides: a European multicentre case-control study (Europe). Cancer Causes Control. 2005;16:1253-1259. (Pubitemid 46179509)
13. Smith BD, Wilson LD. Cutaneous lymphoma. Curr Probl Cancer. 2008;32:43-87.
14. Goodlad JR, Davidson MM, Hollowood K, et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the High-lands of Scotland. Am J Surg Pathol. 2000;24:1279-1285. (Pubitemid 30676842)
15. Ries LAG, Melbert D, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, http://seer.cancer. gov/csr/1975-2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008. Accessed February 2009.
16. Percy C, Fritz A, Ries L, eds. Conversion of Neoplasms by Topography and Morphology from the International Classification of Diseases for Oncology, Second Edition (ICD-O-2) to the International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Bethesda, MD: Cancer Statistics Branch, DCCPS, Surveillance, Epidemiology and End Results Program, National Cancer Institute; 2001.
17. Surveillance, Epidemiology and End Results (SEER) Program, National Cancer Institute, SEER*Stat software version 6.4.4. Surveillance Research Program. http://www.seer.cancer.gov/seerstat. Accessed February 2009.
18. Devesa SS, Donaldson J, Fears T. Graphical presentation of trends in rates. Am J Epidemiol. 1995;141:300-304.
19. Miettinen OS, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213-226.
20. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002;76:27-36.
21. Bouaziz JD, Bastuji-Garin S, Poszepczynska-Guigne E, et al. Relative frequency and survival of patients with primary cutaneous lymphomas: data from a single centre study of 203 patients. Br J Dermatol. 2006;154:1206-1207. (Pubitemid 43727411)
22. Kinney MC, Jones D. Cutaneous T-cell and NK-cell lymphomas: the WHO-EORTC classification and the increasing recognition of specialized tumor types. Am J Clin Pathol. 2007;127:670-686.
23. Willemze R. Primary cutaneous lymphomas. Curr Opin Oncol. 2000;12:419-425.
24. Bogle MA, Riddle CC, Triana EM, et al. Primary cutaneous B-cell lymphoma. J Am Acad Dermatol. 2005;53:479-484.
25. Mirza I, Macpherson N, Paproski S, et al. Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic, and molecular features. J Clin Oncol. 2002;20:647-655. (Pubitemid 34111370)
26. Morales Suarez-Varela MM, Llopis Gonzalez A, Marquina Vila A, Bell J. Mycosis fungoides: review of epidemiological observations. Dermatology. 2000;201:21-28. (Pubitemid 30687523)
27. Goodlad JR, Krajewski AS, Batsone PJ, et al. Primary cutaneous diffuse large B-cell lymphoma: prognostic significance of clinicopathological subtypes. Am J Surg Pathol. 2003;27:1538-1545. (Pubitemid 37486615)
28. Li C, Inagaki H, Kuo T, Huo S, Okaba M, Eimoto T. Primary cutaneous marginal zane B-cell lymphoma: a molecular and clinicopathologic study of 24 Asian cases. Am J Surg Pathol. 2003;27:1061-1069. (Pubitemid 36909527)
29. Wood GS, Kamath NV, Guitart J, et al. Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the US. J Cutan Pathol. 2001;28:502-507. (Pubitemid 33020611)
30. Willemze R. Primary cutaneous B-cell lymphoma: classification and treatment. Curr Opin Oncol. 2006;18:425-431. (Pubitemid 44199836)
31. Liu Q, Ohshima K, Kikuchi M. Primary cutaneous B-cell lymphoma in Japanese patients. Pathol Int. 2000;50:960-966. (Pubitemid 32128472)
32. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265-276.
33. Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium. Blood. 2007;110:695-708.
34. Grange F, Bekkenk MW, Wechsler J, et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol. 2001;19:3602-3610. (Pubitemid 32786274)
35. Boren E, Gershwin ME. Inflamm-aging: autoimmunity, and the immune-risk phenotype. Autoimmun Rev. 2004;3:401-406.
36. Morales MM, Putcha V, Evans HS, et al. Survival of mycosis fungoides in patients in the southeast of England. Dermatology. 2005;211:325-329. (Pubitemid 41642105)
37. Kim EJ, Lin J, Junkins-Hopkins JM, Vittorio CC, AH Rook. Mycosis fungoides and Sézary syndrome: an update. Current Oncology Reports. 2006;8:376-386. (Pubitemid 44336299)
38. Grange F, Hedelin G, Joly P, et al. Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome: the French study group on cutaneous lymphomas. Blood. 1999;93:3637-3642.
39. Beljaards RC, Meijer CJLM, van der Putte SCJ, et al. Primary cutaneous T-cell lymphomas: clinicopathologic features and prognostic parameters of 35 cases other than mycosis fungoides and CD30+ large cell lymphoma. J Pathol. 1994;172:53-60.
40. Bekkenk MW, Vermeer MH, Jansen PM, et al. Peripheral T-cell lymphoma unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood. 2003;102:2213-2219.
41. Vermeer MH, Geelen FA, van Haselen CW, et al. Primary cutaneous large B-cell lymphomas of the legs: a distinct type of cutaneous B-cell lymphoma with an intermediate prognosis: Dutch Cutaneous Lymphoma Working Group. Arch Dermatol. 1996;132:1304-1308.
42. Grange F, Beylot-Barry M, Courville P, et al. Primary cutaneous diffuse large B-Cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol. 2007;143:1144-1150. (Pubitemid 47443366)
43. Clarke CA, Undurraga DM, Harasty PJ, et al. Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev. 2006;15:630-638.
44. Percy C, Van Holten V, eds. For the Working Party coordinated by the International Agency for Research on Cancer. International Classification of Diseases for Oncology: Morphology, Field Trial Edition. Geneva, Switzerland: World Health Organization; 1986.
45. Percy C, Van Holten V, eds. For the Working Party coordinated by the International Agency for Research on Cancer. International Classification of Diseases for Oncology: Morphology, Field Trial Edition. Geneva, Switzerland: World Health Organization; 1988.
46. Percy C, Van Holten V, Muir C, eds. For the Working Party coordinated by the International Agency for Research on Cancer. International Classification of Diseases for Oncology. Field trial Ed, 2nd Ed. Geneva, Switzerland:World Health Organization; 1990.
47. Fritz A, Percy C, Jack A, et al, eds. International Classification of Diseases for Oncology. 3rd Ed. Geneva, Switzerland: World Health Organization; 2000.
48. Clegg LX, Feuer EJ, Midthune DN, Fay MP, Hankey BF. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst. 2002;94:1537-1545. (Pubitemid 35277277)
49. Dores GM, Curtis RE, Anderson WF, Demierre MF. Assessment of delayed reporting of mycosis fungoides and Sezary syndrome in the United States. Arch Dermatol. 2008;144:413-414.
50. Senff NJ, Hoefnagel JJ, Jansen PM, et al. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol. 2007;25:1581-1587.
51. Goodlad JR, Krajewski AS, Batstone PJ, et al. Primary cutaneous follicular lymphoma: a clinicopathologic and molecular study of 16 cases in support of a distinct entity. Am J Surg Pathol. 2002;26:733-741. (Pubitemid 34546938)
52. Kim BK, Surti U, Pandya AG, Swerdlow SH. Primary and secondary cutaneous diffuse large B-cell lymphomas: a multiparameter analysis of 25 cases including fluorescence in situ hybridization for t(14;18) translocation. Am J Surg Pathol. 2003;27:356-364. (Pubitemid 36245801)
53. Grange F, Petrella T, Beylot-Barry M, et al. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. Blood. 2004;103:3662-3668. (Pubitemid 38596279)
54. Alexander DD, Mink PJ, Adami H, et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer. 2007;120:(suppl 12)1-39. (Pubitemid 46732571)
55. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000;92:1240-1251.